BRPI0811516A2 - Compostos e composições como inibidores de c-kit e pdgfr cinase - Google Patents

Compostos e composições como inibidores de c-kit e pdgfr cinase

Info

Publication number: BRPI0811516A2
Authority: BR; Brazil
Prior art keywords: kit; compositions; compounds; kinase inhibitors; pdgfr kinase
Prior art date: 2007-05-04

Application number

BRPI0811516-8A2A

Other languages

English (en)

Inventor

Xiaolin Li

Xiaodong Liu

Valentina Molteni

Donatella Chianelli

Jon Loren Collins

Juliet Nabakka

Timothy Ramsey

Werner Breitenstein

Original Assignee

Irm Llc

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-04

Filing date

2008-05-02

Publication date

2014-11-18

2008-05-02 Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc

2014-11-18 Publication of BRPI0811516A2 publication Critical patent/BRPI0811516A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)

BRPI0811516-8A2A 2007-05-04 2008-05-02 Compostos e composições como inibidores de c-kit e pdgfr cinase BRPI0811516A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91605107P	2007-05-04	2007-05-04
PCT/US2008/062568 WO2008137794A1 (en)	2007-05-04	2008-05-02	Compounds and compositions as c-kit and pdgfr kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0811516A2 true BRPI0811516A2 (pt)	2014-11-18

Family

ID=39595782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811516-8A2A BRPI0811516A2 (pt)	2007-05-04	2008-05-02	Compostos e composições como inibidores de c-kit e pdgfr cinase

Country Status (11)

Country	Link
US (1)	US8338417B2 (pt)
EP (1)	EP2152688A1 (pt)
JP (1)	JP5160637B2 (pt)
KR (1)	KR101145520B1 (pt)
CN (1)	CN101720322A (pt)
AU (1)	AU2008247442B2 (pt)
BR (1)	BRPI0811516A2 (pt)
CA (1)	CA2686382C (pt)
EA (1)	EA019524B1 (pt)
MX (1)	MX2009011951A (pt)
WO (1)	WO2008137794A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2009011950A (es)	2007-05-04	2009-12-11	Irm Llc	Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
ES2368876T3 (es)	2007-08-22	2011-11-23	Irm Llc	Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa.
AU2008289037B2 (en)	2007-08-22	2012-03-01	Novartis Ag	5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
CA2714700C (en)	2008-02-22	2013-07-30	Irm Llc	Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
CA2738026C (en)	2008-09-22	2017-01-24	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
AU2009308465B2 (en)	2008-10-22	2015-02-12	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors
BRPI0914360A2 (pt) *	2008-11-14	2015-08-11	Bayer Cropscience Ag	Derivado de piridil-azinilamino substituído, composto da fórmula (i), composição fungicida, método para controlar fungos fitopatogênicos de culturas e método para combater fungos fitopatogênicos e/ou micotoxinas
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
DK2918588T3 (en)	2010-05-20	2017-08-28	Array Biopharma Inc	Macrocyclic compounds as TRK kinase inhibitors
CN103298787A (zh) *	2010-11-17	2013-09-11	诺瓦提斯公司	3-(氨基芳基)-吡啶化合物
CA2840029C (en)	2011-07-27	2021-07-20	Ab Science	Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)
AR090044A1 (es)	2011-12-21	2014-10-15	Novira Therapeutics Inc	Agentes antivirales para la hepatitis b
SG10201605291WA (en)	2012-08-28	2016-08-30	Janssen Sciences Ireland Uc	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
MX2015008471A (es) *	2012-12-27	2016-10-26	Univ Drexel	Nuevos agentes antivirales contra la infeccion por el virus de la hepatitis b (vhb).
JP6387488B2 (ja)	2013-01-10	2018-09-12	プルモキネ、インコーポレイテッド	非選択的キナーゼ阻害剤
JP6466348B2 (ja)	2013-02-28	2019-02-06	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
WO2014165128A2 (en)	2013-03-12	2014-10-09	Novira Therapeutics, Inc.	Hepatitis b antiviral agents
DK2981536T3 (en)	2013-04-03	2017-09-25	Janssen Sciences Ireland Uc	N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
JO3603B1 (ar)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (pt)	2013-07-25	2018-07-21
CN104458674A (zh) *	2013-09-12	2015-03-25	中国药科大学	一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
CN104458675A (zh) *	2013-09-12	2015-03-25	中国药科大学	一种筛选干细胞因子受体激酶抑制剂高通量筛选方法
CN106132403B (zh)	2013-10-11	2020-04-28	普尔莫凯恩股份有限公司	喷雾干燥制剂
EA034448B1 (ru)	2013-10-23	2020-02-10	Янссен Сайенсиз Айрлэнд Юси	Производные карбоксамида и их применение в качестве медикаментов для лечения гепатита b
US10392349B2 (en)	2014-01-16	2019-08-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en)	2014-01-16	2015-11-10	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (en)	2014-02-05	2020-03-25	Novira Therapeutics Inc.	Combination therapy for treatment of hbv infections
PL3102572T3 (pl)	2014-02-06	2019-04-30	Janssen Sciences Ireland Uc	Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
US9400280B2 (en)	2014-03-27	2016-07-26	Novira Therapeutics, Inc.	Piperidine derivatives and methods of treating hepatitis B infections
US10799505B2 (en)	2014-11-16	2020-10-13	Array Biopharma, Inc.	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
EA201792069A1 (ru)	2015-03-19	2018-04-30	Новира Терапьютикс, Инк.	Производные азокана и азонана и способы лечения инфекций гепатита в
MA44936A1 (fr)	2015-06-01	2021-09-30	Loxo Oncology Inc	Méthodes de diagnostic et de traitement du cancer
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EA035049B1 (ru)	2015-07-16	2020-04-22	Аррэй Байофарма Инк.	СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
WO2017059059A1 (en)	2015-09-29	2017-04-06	Novira Therapeutics, Inc.	Crystalline forms of a hepatitis b antiviral agent
KR20180102544A (ko)	2015-10-26	2018-09-17	더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트	Trk 억제제-내성 암에서의 점 돌연변이 및 이의 관련 방법
ES2938341T3 (es) *	2016-03-07	2023-04-10	Enanta Pharm Inc	Agentes antivirales contra la hepatitis B
PL3439663T3 (pl)	2016-04-04	2024-11-18	Loxo Oncology, Inc.	Sposoby leczenia nowotworów wieku dziecięcego
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
NZ747135A (en)	2016-04-04	2025-05-02	Loxo Oncology Inc	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JP2019511542A (ja)	2016-04-15	2019-04-25	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	カプシド集合阻害剤を含む組み合わせ及び方法
RS61463B1 (sr)	2016-05-18	2021-03-31	Loxo Oncology Inc	Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
EP3532063A4 (en)	2016-10-27	2020-07-22	Pulmokine, Inc.	POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION
EP3333162A1 (en) *	2016-12-12	2018-06-13	Silesian Catalysts sp. z o.o.	Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
US11168090B2 (en)	2017-01-18	2021-11-09	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI811236B (zh)	2017-08-28	2023-08-11	美商因那塔製藥公司	B型肝炎抗病毒試劑
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
MA50456A (fr)	2017-10-26	2020-09-02	Array Biopharma Inc	Formulations d'un inhibiteur de kinase trk macrocyclique
CN111971286B (zh)	2018-01-18	2023-04-14	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
WO2019143991A1 (en)	2018-01-18	2019-07-25	Array Biopharma Inc.	SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11472802B2 (en)	2018-01-18	2022-10-18	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
EP3765011A1 (en)	2018-03-14	2021-01-20	Janssen Sciences Ireland Unlimited Company	Capsid assembly modulator dosing regimen
CA3095366A1 (en)	2018-03-29	2019-10-03	Loxo Oncology, Inc.	Treatment of trk-associated cancers
JP7286755B2 (ja)	2018-07-31	2023-06-05	ロクソオンコロジー，インコーポレイテッド	（ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤
JP2022500383A (ja)	2018-09-10	2022-01-04	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
BR112021009854A2 (pt)	2018-11-21	2021-08-17	Enanta Pharmaceuticals, Inc.	heterociclos funcionalizados como agentes antivirais
WO2020131674A1 (en)	2018-12-19	2020-06-25	Array Biopharma Inc.	7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
US12180207B2 (en)	2018-12-19	2024-12-31	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
BR112021015618A2 (pt)	2019-02-22	2021-10-05	Janssen Sciences Ireland Unlimited Company	Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv
MA55879A (fr)	2019-05-06	2022-03-16	Janssen Sciences Ireland Unlimited Co	Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
US11802125B2 (en)	2020-03-16	2023-10-31	Enanta Pharmaceuticals, Inc.	Functionalized heterocyclic compounds as antiviral agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5516775A (en) *	1992-08-31	1996-05-14	Ciba-Geigy Corporation	Further use of pyrimidine derivatives
US20030176443A1 (en)	2001-05-16	2003-09-18	Matthias Stein-Gerlach	Pyridylpyrimidine derivatives as effective compounds against prion diseases
CA2446756C (en) *	2001-06-01	2011-03-08	Vertex Pharmaceuticals Incorporated	Thiazole compounds useful as inhibitors of protein kinase
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en)	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
PL1635835T3 (pl) *	2003-06-13	2010-06-30	Novartis Ag	Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
JP5184887B2 (ja) *	2004-09-09	2013-04-17	ナトコファーマリミテッド	ｂｃｒ−ａｂｌキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体
AU2005325676A1 (en)	2004-12-23	2006-08-03	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
KR100674813B1 (ko)	2005-08-05	2007-01-29	일양약품주식회사	Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
KR20090075889A (ko)	2006-11-03	2009-07-09	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물 및 조성물
BRPI0720635A2 (pt) *	2006-12-22	2014-01-07	Novartis Ag	Compostos orgânicos e seus usos

2008
- 2008-05-02 AU AU2008247442A patent/AU2008247442B2/en not_active Ceased
- 2008-05-02 US US12/598,922 patent/US8338417B2/en not_active Expired - Fee Related
- 2008-05-02 WO PCT/US2008/062568 patent/WO2008137794A1/en active Application Filing
- 2008-05-02 EP EP08747596A patent/EP2152688A1/en not_active Withdrawn
- 2008-05-02 CA CA2686382A patent/CA2686382C/en not_active Expired - Fee Related
- 2008-05-02 MX MX2009011951A patent/MX2009011951A/es active IP Right Grant
- 2008-05-02 KR KR1020097025297A patent/KR101145520B1/ko not_active Expired - Fee Related
- 2008-05-02 CN CN200880023168A patent/CN101720322A/zh active Pending
- 2008-05-02 JP JP2010507577A patent/JP5160637B2/ja not_active Expired - Fee Related
- 2008-05-02 EA EA200901486A patent/EA019524B1/ru not_active IP Right Cessation
- 2008-05-02 BR BRPI0811516-8A2A patent/BRPI0811516A2/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2008137794A1 (en)	2008-11-13
CN101720322A (zh)	2010-06-02
KR101145520B1 (ko)	2012-05-16
EP2152688A1 (en)	2010-02-17
JP5160637B2 (ja)	2013-03-13
US8338417B2 (en)	2012-12-25
MX2009011951A (es)	2009-12-11
AU2008247442B2 (en)	2013-01-10
AU2008247442A1 (en)	2008-11-13
CA2686382A1 (en)	2008-11-13
JP2010526151A (ja)	2010-07-29
CA2686382C (en)	2013-09-17
EA200901486A1 (ru)	2010-06-30
US20100234406A1 (en)	2010-09-16
EA019524B1 (ru)	2014-04-30
KR20090130427A (ko)	2009-12-23

Publication	Publication Date	Title
BRPI0811516A2 (pt)	2014-11-18	Compostos e composições como inibidores de c-kit e pdgfr cinase
BRPI0908849A2 (pt)	2015-08-25	Composto e composições como c-kit e inibidores de pdgfr quinase
CY2019027I2 (el)	2019-11-27	Παραγωγα φωσφορου ως αναστολεις κινασης
LTPA2019006I1 (lt)	2019-03-25	Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai
BRPI0914652A2 (pt)	2017-06-06	compostos e composições como inibidores de quinase
BRPI0911228A2 (pt)	2017-05-30	compostos e composições como inibidores de proteínas quinase
BRPI0912668A2 (pt)	2016-01-26	composto e composições como inibidores de quinase
BRPI0906973A2 (pt)	2015-07-14	Compostos e composições como inibidores de cinase.
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0811517A2 (pt)	2014-11-18	Compostos e composições como inibidores de c-kit e pdgfr cinase.
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0910979A2 (pt)	2016-01-05	compostos e composições como inibidores de quinase
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
BRPI0811065A2 (pt)	2014-12-02	Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0719797A2 (pt)	2017-10-24	compostos e composições como inibidores de proteína cinase
BR112012004448A2 (pt)	2017-05-30	"compostos e composições como inibidores de proteína cinase"
BRPI0820544A2 (pt)	2015-06-16	4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0812825A2 (pt)	2014-12-09	Derivados ftalazinona como inibidores de parp-1
BRPI0813499A2 (pt)	2015-01-06	Compostos úteis como inibidores da quinase raf
BRPI0914545A2 (pt)	2017-05-23	compostos e composições como inibidores de quinase
BRPI0912475A2 (pt)	2018-01-09	compostos como inibidores de quinase
CO6900141A2 (es)	2014-03-20	Compuestos y composiciones como inhibidores de la quinasa c-kit
BRPI0920239A2 (pt)	2019-09-24	compostos heterocíclicos como inibidores de proteínas quinases
BRPI0908494A2 (pt)	2015-08-11	Inibidores de pirrolopirazina quinase

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.